Distinctive Molecular Risk Factors Between MDS and MDS / AML Defined by ICC
American Journal of Hematology · 2026
DOI: 10.1002/ajh.70296 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, 2026. Verfasst von Ting-Juan Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Affiliated People's Hospital of Jiangsu University, Zhenjiang Clinical Research Center of Hematology, Zhenjiang, Jiangs…. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, Research Project of Jiangsu Commission of Health.
Abstract (Originalsprache)
Myelodysplastic syndromes/neoplasms (MDS) represent a heterogeneous group of clonal hematopoietic stem cell diseases with high risks of acute myeloid leukemia (AML) transformation. To emphasize the characteristics of AML transformation, the International Consensus Classification (ICC) has classified MDS with excess blasts (10%–19%) as MDS/AML. Recently, a clinical‐molecular prognostic model International Prognostic Scoring System Molecular (IPSS‐M) is developed, which improves the risk stratification of MDS. However, these molecular risk factors were analyzed in a cohort of highly heterogeneous patients with MDS including MDS/AML. Herein, we re‐evaluated and compared the molecular risk factors in MDS (blasts < 10%) and MDS/AML (blasts 10%–19%) defined by ICC. Notably, there is a significant difference in molecular landscape between MDS and MDS/AML. Importantly, most of the risk factors presented in MDS was not shown in MDS/AML except for TP53 aberrations and FLT3‐ITD mutation. Since the IPSS‐R and IPSS‐M showed a poorly prognostic separation for MDS/AML patients, we further established a new prognostic model MDS/AML‐IPSS‐M and significantly improved its prognostic discrimination ability. Taking together, our research findings enhance the understanding of the molecular biology of MDS and can provide important guidance for the clinical identification of MDS/AML patients that might benefit clinical decision‐making and therapeutic research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The Affiliated People's Hospital of Jiangsu University, Zhenjiang Clinical Research Center of Hematology, Zhenjiang, Jiangsu, China.
- Institute of Hematology, Jiangsu University, Zhenjiang, Jiangsu, China.
- The Key Lab of Precision Diagnosis and Treatment in Hematologic Malignancies of Zhenjiang City, Zhenjiang, Jiangsu, China.
- Jiangsu Key Laboratory of Medical Science and Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China.
ORCID-Profile: Jing-Dong Zhou
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
- Research Project of Jiangsu Commission of Health
Zitieren
APA
Zhang, T. J., Zhao, Y. J., Xu, Z. J., Qian, J., & Zhou, J. D. (2026). Distinctive Molecular Risk Factors Between MDS and MDS / AML Defined by ICC. American Journal of Hematology. https://doi.org/10.1002/ajh.70296
Vancouver
Zhang TJ, Zhao YJ, Xu ZJ, Qian J, Zhou JD. Distinctive Molecular Risk Factors Between MDS and MDS / AML Defined by ICC. American Journal of Hematology. 2026. doi:10.1002/ajh.70296
BibTeX
@article{Zhang2026,
author = {Zhang, Ting-Juan and Zhao, Yang-Jing and Xu, Zi-Jun and Qian, Jun and Zhou, Jing-Dong},
title = {Distinctive Molecular Risk Factors Between MDS and MDS / AML Defined by ICC},
journal = {American Journal of Hematology},
year = {2026},
doi = {10.1002/ajh.70296}
}
EUVIMED